Nikulin S V, Mnafki Krainova N A, Shilin S A, Gazizov I N, Maltseva D V
Scientific Research Center Bioclinicum, Moscow, 115088 Russia.
Moscow Institute of Physics and Technology (State University), Dolgoprudny, Moscow oblast, 141701 Russia.
Mol Biol (Mosk). 2018 Jul-Aug;52(4):675-682. doi: 10.1134/S0026898418040146.
The mistletoe lectin viscumin (MLI) is a ribosome-inactivating protein from Viscum album widely used in cancer therapy. Its antitumor properties are due to its immunomodulating action, previously demonstrated in experiments involving intravenous, subcutaneous, and oral administration of viscumin. To investigate whether viscumin has a cytotoxic effect on the intestinal epithelium, its safety was assessed using (i) impedance spectroscopy to measure the integrity of the colorectal adenocarcinoma Caco-2 cell monolayer after exposure to viscumin and (ii) a novel technique of determining the portion of viscumin-inactivated ribosomes. It was shown that inactivation of at least 20% of the ribosomes within 6 h did not lead to disruption of the Caco-2 cell monolayer or alter the physicochemical parameters of enterocyte membranes.
槲寄生凝集素viscumin（MLI）是一种来自欧洲槲寄生的核糖体失活蛋白，广泛应用于癌症治疗。其抗肿瘤特性归因于其免疫调节作用，此前在涉及静脉内、皮下和口服viscumin的实验中已得到证实。为了研究viscumin对肠道上皮细胞是否具有细胞毒性作用，使用（i）阻抗光谱法测量暴露于viscumin后结肠腺癌Caco-2细胞单层的完整性，以及（ii）一种确定viscumin失活核糖体部分的新技术来评估其安全性。结果表明，在6小时内至少20%的核糖体失活不会导致Caco-2细胞单层的破坏，也不会改变肠细胞膜的物理化学参数。
